ABT · Abbott Laboratories - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B |
| Cost of Revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | $15.00B |
| Gross Profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B |
| R&D | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B |
| SG&A | $12.33B | $11.70B | $10.95B | $11.25B | $11.32B | $9.70B |
| Total Operating Expenses | $36.27B | $35.13B | $33.63B | $35.29B | $34.65B | $29.25B |
| D&A | $1.43B | $1.34B | $1.28B | $1.25B | $1.49B | $1.20B |
| Operating Income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B |
| Interest Expense | $493.00M | $559.00M | $637.00M | $558.00M | $533.00M | $546.00M |
| Income Tax | $1.94B | ($6.39B) | $941.00M | $1.37B | $1.14B | $497.00M |
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B |
| EPS - Basic | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 | $2.52 |
| EPS - Diluted | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B |
| Accounts Receivable | $7.93B | $6.92B | $6.57B | $6.22B | $6.49B | $6.41B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B | $5.01B |
| Accounts Payable | $4.24B | $4.20B | $4.29B | $4.61B | $4.41B | $3.95B |
| Current Assets | $26.00B | $23.66B | $22.67B | $25.22B | $24.24B | $20.44B |
| Total Assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B |
| Current Liabilities | $16.50B | $14.16B | $13.84B | $15.49B | $13.11B | $11.91B |
| Long-term Debt | $9.90B | $12.63B | $13.60B | $14.52B | $17.30B | $18.53B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B |
| Retained Earnings | $49.78B | $47.26B | $37.55B | $35.26B | $31.53B | $27.63B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B |
| Investing Cash Flow | ($2.42B) | ($2.34B) | ($3.13B) | ($1.74B) | ($2.01B) | ($2.21B) |
| Financing Cash Flow | ($6.31B) | ($5.40B) | ($7.09B) | ($7.64B) | ($5.49B) | ($2.78B) |
| CapEx | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B | $2.18B |
| Free Cash Flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B | $5.72B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | 56.6% |
| Operating margin | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | 15.5% |
| EBITDA margin | 21.4% | 19.5% | 19.3% | 22.0% | 23.0% | 18.9% |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% |
| Free cash flow margin | 16.7% | 15.1% | 12.6% | 17.9% | 20.1% | 16.5% |
| FCF / Net income | 1.13 | 0.47 | 0.88 | 1.13 | 1.22 | 1.27 |
| R&D / Revenue | 6.6% | 6.8% | 6.8% | 6.6% | 6.4% | 7.0% |
| SG&A / Revenue | 27.8% | 27.9% | 27.3% | 25.8% | 26.3% | 28.0% |
| Effective tax rate | 22.9% | -91.1% | 14.1% | 16.5% | 13.9% | 10.0% |
| Return on assets | 7.5% | 16.5% | 7.8% | 9.3% | 9.4% | 6.2% |
| Return on equity | 12.5% | 28.1% | 14.8% | 18.9% | 19.8% | 13.7% |
| Return on invested capital | 10.0% | 11.3% | 10.7% | 13.6% | 13.7% | 9.4% |
| Liquidity | ||||||
| Current ratio | 1.58 | 1.67 | 1.64 | 1.63 | 1.85 | 1.72 |
| Quick ratio | 1.18 | 1.23 | 1.16 | 1.23 | 1.46 | 1.30 |
| Cash ratio | 0.52 | 0.54 | 0.50 | 0.64 | 0.75 | 0.57 |
| Leverage | ||||||
| Debt / Equity | 0.19 | 0.26 | 0.35 | 0.40 | 0.48 | 0.57 |
| Debt / Assets | 0.11 | 0.16 | 0.19 | 0.20 | 0.23 | 0.26 |
| Debt / EBITDA | 1.04 | 1.55 | 1.75 | 1.51 | 1.74 | 2.83 |
| Interest coverage | 16.3x | 12.2x | 10.2x | 15.0x | 15.8x | 9.8x |
| Equity multiplier | 1.66 | 1.71 | 1.90 | 2.03 | 2.10 | 2.21 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.51 | 0.52 | 0.55 | 0.59 | 0.57 | 0.48 |
| Inventory turnover | 2.98 | 3.02 | 2.74 | 3.10 | 3.59 | 2.99 |
| Days sales outstanding | 65d | 60d | 60d | 52d | 55d | 68d |
| Days inventory outstanding | 123d | 121d | 133d | 118d | 102d | 122d |
| Days payable outstanding | 80d | 82d | 87d | 88d | 87d | 96d |
| Cash conversion cycle | 108d | 99d | 106d | 82d | 70d | 94d |
| Valuation | ||||||
| P / E | 33.7x | 14.8x | 33.8x | 28.1x | 35.7x | 43.8x |
| P / B | 4.2x | 4.1x | 5.0x | 5.3x | 7.0x | 6.0x |
| P / S | 4.9x | 4.7x | 4.8x | 4.4x | 5.8x | 5.7x |
| EV / EBITDA | 23.2x | 24.8x | 25.7x | 20.6x | 26.1x | 31.6x |
| Growth | ||||||
| Revenue growth (YoY) | 5.7% | 4.6% | -8.1% | 1.3% | 24.5% | 8.5% |
| Revenue CAGR (3y) | 0.5% | -0.9% | 5.0% | 11.0% | 27.4% | 8.1% |
| Revenue CAGR (5y) | 5.1% | 5.6% | 14.0% | 9.8% | 15.6% | 11.1% |
| Gross profit growth (YoY) | 7.6% | 5.0% | -9.7% | -0.1% | 25.2% | 5.0% |
| Operating income growth (YoY) | 18.0% | 5.4% | -22.5% | -0.7% | 57.3% | 18.2% |
| Net income growth (YoY) | -51.3% | 134.2% | -17.5% | -2.0% | 57.3% | 21.9% |
| EPS growth (YoY) | -51.3% | 134.4% | -16.6% | -0.8% | 57.6% | 21.4% |
| EPS CAGR (3y) | -1.6% | 24.7% | 9.3% | 23.8% | 43.6% | 110.0% |
| EPS CAGR (5y) | 8.3% | 30.0% | 19.6% | 70.7% | 33.2% | -3.1% |
| FCF growth (YoY) | 16.4% | 25.5% | -35.2% | -9.8% | 51.1% | 27.3% |
| FCF CAGR (5y) | 5.3% | 7.1% | 0.6% | 12.0% | 32.9% | 25.3% |
| Book value growth (YoY) | 9.4% | 23.5% | 5.2% | 2.5% | 9.2% | 5.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$16.15B totalDiagnostic Products$5.36B · 33.2%
Established Pharmaceutical Products$4.17B · 25.8%
Nutritional Products$3.97B · 24.6%
Medical Devices$2.65B · 16.4%
Product / service
$297.00M totalCOVID19 Testing$297.00M · 100.0%
Geographic
$33.53B totalAll Other Countries$15.98B · 47.7%
Non Us$4.17B · 12.4%
DE$2.76B · 8.2%
US$2.16B · 6.4%
CN$1.91B · 5.7%
CH$1.87B · 5.6%
IN$1.87B · 5.6%
JP$1.48B · 4.4%
GB$1.34B · 4.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ABBOTT LABORATORIES against the 5 most active filers in the same SIC group.
Dividends
$2.44/share trailing 12 months · +7.0% YoY
| Ex-date | Per share |
|---|---|
| Apr 15, 2026 | $0.6300 |
| Jan 15, 2026 | $0.6300 |
| Oct 15, 2025 | $0.5900 |
| Jul 15, 2025 | $0.5900 |
| Apr 15, 2025 | $0.5900 |
| Jan 15, 2025 | $0.5900 |
| Oct 15, 2024 | $0.5500 |
| Jul 15, 2024 | $0.5500 |
| Apr 12, 2024 | $0.5500 |
| Jan 11, 2024 | $0.5500 |
| Oct 12, 2023 | $0.5100 |
| Jul 13, 2023 | $0.5100 |
| Apr 13, 2023 | $0.5100 |
| Jan 12, 2023 | $0.5100 |
| Oct 13, 2022 | $0.4700 |
| Jul 14, 2022 | $0.4700 |
| Apr 13, 2022 | $0.4700 |
| Jan 13, 2022 | $0.4700 |
| Oct 14, 2021 | $0.4500 |
| Jul 14, 2021 | $0.4500 |
| Apr 14, 2021 | $0.4500 |
| Jan 14, 2021 | $0.4500 |
| Oct 14, 2020 | $0.3600 |
| Jul 14, 2020 | $0.3600 |